new device for delivering nebulised antibiotics

[Guest guest]

     Espicom Business Intelligence

                                 March 14, 2003

HEADLINE: Profile Therapeutics offers new device for delivering nebulised

antibiotics to CF patients

   Profile Therapeutics has announced the UK launch of the Prodose AAD

system, a

device incorporating intelligent inhalation technology that is designed

to

deliver consistent, accurate doses of nebulised antibiotic to cystic

fibrosis

(CF) patients.The Prodose AAD system delivers pulses of aerosolised

antibiotic

into the first half of the patient's inhalation, until the dose has been

administered. The delivery of antibiotic into the inspiratory phase of

the

respiratory cycle addresses the two key issues associated with drug

delivery to

the lungs: variable dosing due to poor inhalation technique and poor

compliance

with the device. In a recent multicentre, multinational trial, 83 per

cent of

doses started with AAD technology were completed correctly, compared to

only 43

per cent started with conventional high-output nebuliser systems.

Profile's

Prodose AAD system delivers Promixin, a branded version of colistimethate

sodium

(colistin), which is recommended by the Cystic Fibrosis Trust as

first-line

therapy for treatment of pseudomonas aeruginosa lung infection. When

doctors

prescribe Promixin, their patient can receive the Prodose AAD system (on

long

term loan) complete with a comprehensive patient support programme, aimed

at

providing advice on the use of the system and supplying necessary

replacement

parts on a regular basis.A preprogrammed Prodose Disc is also supplied

with the

Promixin for nebulisation drug pack. The patient slots the Prodose Disc

into the

hand piece of the Prodose AAD system and regulates the amount of drug

delivered

through the delivery system, with messages about the dose delivered to

the

device via radio frequency technology.  Once activated, AAD technology

constantly monitors the patient's breathing pattern and matches the

release of

drug per breath to the individual patient. The device also gives feedback

to the

patient, informing them that drug is being delivered and when the

treatment has

been completed. According to Profile, the Prodose AAD system delivers a

measured

dose of antibiotic in approximately four minutes compared with ten

minutes for a

conventional nebuliser when evaluated using UK testing standards.

Furthermore,

ease of use and added convenience led to 81 per cent of patients

expressing a

preference for the AAD technology over their conventional nebuliser in a

clinical trial.

Becki

YOUR FAVORITE LilGooberGirl

YOUNGLUNG EMAIL SUPPORT LIST

www.topica.com/lists/younglung

Pediatric Interstitial Lung Disease Society

http://groups.yahoo.com/group/InterstitialLung_Kids/